AstraZeneca plc (AZN) Price Target Increased to GBX 4,150 by Analysts at HSBC Holdings plc

AstraZeneca plc (LON:AZN) had its target price upped by HSBC Holdings plc from GBX 4,100 ($53.90) to GBX 4,150 ($54.56) in a research report sent to investors on Monday morning. They currently have a reduce rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Citigroup Inc. restated a buy rating and set a GBX 6,000 ($78.89) target price on shares of AstraZeneca plc in a research report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($82.83) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Wednesday, September 13th. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.11) target price on shares of AstraZeneca plc in a research report on Tuesday, September 5th. Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.94) target price on shares of AstraZeneca plc in a research report on Friday, June 30th. Finally, Natixis upgraded shares of AstraZeneca plc from a neutral rating to a buy rating and boosted their target price for the stock from GBX 5,000 ($65.74) to GBX 5,738 ($75.44) in a research report on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of GBX 5,113.55 ($67.23).

AstraZeneca plc (LON AZN) opened at 5158.00 on Monday. The company has a 50 day moving average of GBX 4,765.75 and a 200 day moving average of GBX 4,899.97. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The firm’s market capitalization is GBX 65.30 billion.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://ledgergazette.com/2017/10/10/astrazeneca-plc-azn-price-target-increased-to-gbx-4150-by-analysts-at-hsbc-holdings-plc.html.

The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.91) per share. This represents a dividend yield of 1.35%. The ex-dividend date

Several other equities research analysts have also commented on the stock. Citigroup Inc. restated a buy rating and set a GBX 6,000 ($78.89) target price on shares of AstraZeneca plc in a research report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($82.83) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Wednesday, September 13th. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.11) target price on shares of AstraZeneca plc in a research report on Tuesday, September 5th. Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.94) target price on shares of AstraZeneca plc in a research report on Friday, June 30th. Finally, Natixis upgraded shares of AstraZeneca plc from a neutral rating to a buy rating and boosted their target price for the stock from GBX 5,000 ($65.74) to GBX 5,738 ($75.44) in a research report on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of GBX 5,113.55 ($67.23).

AstraZeneca plc (LON AZN) opened at 5158.00 on Monday. The company has a 50 day moving average of GBX 4,765.75 and a 200 day moving average of GBX 4,899.97. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The firm’s market capitalization is GBX 65.30 billion.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://ledgergazette.com/2017/10/10/astrazeneca-plc-azn-price-target-increased-to-gbx-4150-by-analysts-at-hsbc-holdings-plc.html.

The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.91) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($57.45) per share, with a total value of £1,704.30 ($2,240.73).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply